期刊简介
1985年创刊，中华医学会主办。本刊是反映我国当代及与国外合作的，在内分泌代谢病学领域内临床与科研最新成果的高级学术刊物。在强调刊文的先进性、科学性与新颖性的同时，也十分重视临床的实用性和论文的可读性。本刊设指南与共识、述评、专论、论坛、临床研究、基础研究、综述、讲座、临诊应对、当年学术进展与动态、临床经验交流、新药研究、学术争鸣及国外期刊论文评论等栏目。本刊的读者对象主要为各级从事临床和基础内分泌代谢病学工作的医、教、研人员及研究生，以及内、外、儿、妇科以及神经、泌尿、老年、营养等相关科室的人员。
往期目录
-
2000
-
2001
-
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
首页>中华内分泌代谢杂志
- 杂志名称：中华内分泌代谢杂志
- 主管单位：中国科学技术协会
- 主办单位：中华医学会
- 国际刊号：1000-6699
- 国内刊号：31-1282/R
- 出版周期：月刊
期刊荣誉：92年12月获中华医学会华瑞杯优秀期刊三等奖期刊收录：CA 化学文摘(美), 维普收录(中), 北大核心期刊(中国人文社会科学核心期刊), 万方收录(中), 国家图书馆馆藏, 统计源核心期刊(中国科技论文核心期刊), JST 日本科学技术振兴机构数据库(日), 上海图书馆馆藏, 知网收录(中), CSCD 中国科学引文数据库来源期刊(含扩展版)
Basal insulin and GLP-1 receptor agonists:A complementary approach to achievement of glycemic control
Juan Pablo Frías
关键词：diabetes mellitus, type 2, insulin, Glucagon-like peptide 1, Combination Therapy, Disease Management
摘要：Today,we are fortunate to have multiple therapeutic agents that address the pathophysiologic defects resulting in hyperglycemia in type 2 diabetes. Evidence from clinical trials,as well as experience in practice, support recent treatment guidelines which call for the early combination of agents with complementary mechanisms of action to help patients achieve and maintain individualized glycemic targets. In patients with type 2 diabetes not achieving adequate glycemic control despite the addition of basal insulin,one such combination that has been shown to be safe and effective in multiple clinical trials, is the combination of basal insulin and a glucagon-like peptide 1 receptor agonist(GLP-1 RA). Through complimentary mechanisms of action,this regimen improves glycemic control and does so with significantly less hypoglycemia and with favorable effects on body weight compared with the addition of rapid-acting insulin(e.g.,basal-bolus insulin regimen). The addition of a GLP-1 RA should therefore be considered in patients with type 2 diabetes suboptimally controlled with basal insulin.
友情链接